Arca
Skip to content

Cytomegalovirus

Drug research and approvals for cytomegalovirus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 65 studies of cytomegalovirus are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, FDA has 8 approved and 14 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 65
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 8
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 65 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 13; search them all in Canada trials
Oct 21, 2025Clear-cmv: combination letermovir and standard of care antiviral for enhanced antiviral response in cytomegalovirus infection in lung transplant recipients: a…LETERMOVIRUNIVERSITY HEALTH NETWORKPending
Aug 13, 2024Letermovir prophylaxis for cytomegalovirus in pediatric hematopoietic cell transplantationLETERMOVIRCHILDRENS ONCOLOGY GROUPOngoing
Aug 10, 2022A phase 1/2a open-label dose-ranging and observer-blind placebo-controlled, safety and immunogenicity study of mrna-1647 cytomegalovirus vaccine in female and…MRNA-1647MODERNATX, INC.Closed
Mar 2, 2022Influence of a 3-month letermovir treatment on gut inflammation in art-treated hiv-infected persons in an open labelled controlled randomized studyLETERMOVIRDR JEAN-PIERRE ROUTYClosed
Nov 5, 2021A phase 3, randomized, observer-blind, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of mrna-1647 cytomegalovirus (cmv) vaccine…MRNA-1647MODERNATX, INC.Ongoing
Apr 21, 2021Randomized controlled trial of valganciclovir for cytomegalovirus infected hearing impaired infants (valear trial)VALGANCICLOVIRCHILDRENS HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTEPending
May 4, 2018Double-blind, randomized, placebo-controlled phase 2b, multi-center study to evaluate the safety, tolerability, efficacy and immunogenicity of a 2-dose and a…V160 (HUMAN CYTOMEGALOVIRUS [HCMV] VACCINE) / MAPA (MERCK ALUMINUM PHOSPHATE…Merck & Co. (MSD)Ongoing
Jun 6, 2017A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to…MARIBAVIR (SHP620)/ VALGANCICLOVIRTakeda Pharmaceuticals USAOngoing
Dec 6, 2016A phase 3, multicenter, randomized, open-label, active-controlled study to assess the efficacy and safety of maribavir treatment compared to…MARIBAVIR (SHP620)Takeda Pharmaceuticals USAClosed
Dec 17, 2015A randomized, double-blind, multicenter, phase 3 study of the efficacy, safety, and tolerability of brincidofovir (bcv) versus valganciclovir (vgcv) for the…BRINCIDOFOVIR (CMX001)ChimerixPending

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 22
Aug 30, 2024Prevymisprophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least…Merck Sharp & Dohme LLCApproved
Aug 30, 2024Prevymisprophylaxis of cytomegalovirus (CMV) disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are…Merck Sharp & Dohme LLCApproved
Jun 5, 2023Prevymisprophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV…Merck Sharp & Dohme LLCApproved
Nov 23, 2021LivtencityTreatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus…Takeda Pharmaceuticals U.S.A., Inc.Approved
Nov 8, 2017PREVYMISProphylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem…Merck Sharp & Dohme LLCApproved
Dec 4, 1998CytoGam#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney…CSL Behring LLCApproved
Mar 4, 1996Vitrasert ImplantTreatment of CMV retinitis in patients with acquired immunodeficiency syndrome.Bausch & Lomb Surgical, Chiron Vision ProductsApproved
Jun 23, 1989CytoveneTreatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.Syntex (USA), Inc.Approved
Jan 5, 2017cytomegalovirus specific cytotoxic T lymphocytesTreatment of cytomegalovirus infection in severely immunocompromised patientsViraCyte, LLCDesignated
Nov 29, 2010filociclovirTreatment of active cytomegalovirus infectionsMicrobiotix, Inc.Designated
Feb 1, 2007maribavirPrevention of cytomegalovirus viremia and disease in the populations at risk.Takeda Pharmaceuticals U.S.A., Inc.Designated
Dec 20, 2006Human cytomegalovirus immunoglobulinPrevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant womenBiotest Pharmaceuticals Corporation's (BPC)Designated
Jun 3, 2005Cytomegalovirus DNA vaccine with plasmids expressing pp65…Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell…Astellas Pharma Global Development, Inc.Designated
Nov 15, 1991Monoclonal antibody to cytomegalovirus (human)Treatment of cytomegalovirus retinitis in patients with AIDS.Protein Design Labs, Inc.Designated
Sep 13, 1991Monoclonal antibody to cytomegalovirus (human)Prophylaxis of cytomegalovirus disease in patients undergoing solid organ transplantation.Protein Design Labs, Inc.Designated

Medicines Authorised in the EU

Newest first
Nov 9, 2022Livtencitymaribavir · orphanTakeda Pharmaceuticals International AG Ireland BranchEMA ↗
Jan 8, 2018Prevymisletermovir · orphanMerck Sharp & Dohme B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.